{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-013646","form_type":"8-K","ticker":"NRC","cik":"0000070487","company_name":"NRC HEALTH","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.654583+00:00","generated_at":"2026-05-15T03:24:31.889028+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NRC Health amends exec stock awards, eliminates repurchase right; expects $9.4M Q2 expense","bullets":["Committee amended grants to CEO Trent Green (500k shares), COO Helen Hrdy (100k), and Chief Corp Dev Officer Andrew Monich (100k) to eliminate repurchase right.","Cash bonuses approved: ~$1.9M for Green, ~$0.5M each for Hrdy and Monich to cover estimated taxes from award changes.","Expected Q2 2026 expense of $9.4M: ~$6.5M non-cash accelerated equity comp and ~$2.9M cash bonus expense.","Effective tax rate impacted by non-deductibility of amounts; future period charges eliminated."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-013646","json":"https://secwatch.observer/filing/0001437749-26-013646.json","markdown":"https://secwatch.observer/filing/0001437749-26-013646.md","text":"https://secwatch.observer/filing/0001437749-26-013646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/70487/000143774926013646/0001437749-26-013646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/70487/000143774926013646/nrc20260425_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:24:31.889028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}